Literature DB >> 22142845

Expanding the utility of heptamer-type sgRNA for TRUE gene silencing.

Takako Sano1, Masayuki Takahashi, Tadasuke Nozaki, Yoshiaki Takahashi, Masato Tamura, Masayuki Nashimoto.   

Abstract

tRNase Z(L)-utilizing efficacious gene silencing (TRUE gene silencing) is a novel technology for suppressing gene expression. TRUE gene silencing is based on a unique enzymatic property of mammalian tRNase Z(L), which is that it can cleave any target RNA at any desired site by recognizing a pre-tRNA-like or micro-pre-tRNA-like complex formed between the target RNA and artificial small guide RNA (sgRNA). sgRNA is divided into four groups, 5'-half-tRNA, RNA heptamer, hook RNA, and ∼14-nt linear RNA. One of the final destinations of TRUE gene silencing is to generate cancer therapeutic sgRNAs, and from a pharmacological point of view, heptamer-type sgRNA appears to be the most appropriate for this purpose. In this paper, we present two strategies to expand the utility of heptamer-type sgRNA: one is about locked nucleic acid (LNA) modifications of heptamers and the other is about usage of double heptamers. We showed that RNA heptamers with LNA modifications can work as sgRNA in vitro and in vivo. We also demonstrated that two consecutively aligned heptamers can guide target RNA cleavage by human tRNase Z(L) as efficiently as a corresponding 14-nt sgRNA in vitro and that a double heptamer can work much better than a 14-nt sgRNA in vivo.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22142845     DOI: 10.1016/j.bbrc.2011.11.091

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

Review 1.  TRUE Gene Silencing.

Authors:  Masayuki Nashimoto
Journal:  Int J Mol Sci       Date:  2022-05-11       Impact factor: 6.208

2.  TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents.

Authors:  Arisa Haino; Tatsuya Ishikawa; Mineaki Seki; Masayuki Nashimoto
Journal:  J Vis Exp       Date:  2016-06-02       Impact factor: 1.355

3.  Elimination of specific miRNAs by naked 14-nt sgRNAs.

Authors:  Masayuki Takahashi; Reyad A Elbarbary; Mayumi Abe; Mari Sato; Tetsuo Yoshida; Yoji Yamada; Masato Tamura; Masayuki Nashimoto
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

4.  Growth inhibition of head and neck squamous cell carcinoma cells by sgRNA targeting the cyclin D1 mRNA based on TRUE gene silencing.

Authors:  Satoshi Iizuka; Nobuhiko Oridate; Masayuki Nashimoto; Satoshi Fukuda; Masato Tamura
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

5.  Potential small guide RNAs for tRNase ZL from human plasma, peripheral blood mononuclear cells, and cultured cell lines.

Authors:  Sho Ninomiya; Mitsuoki Kawano; Takashi Abe; Tatsuya Ishikawa; Masayuki Takahashi; Masato Tamura; Yoshiaki Takahashi; Masayuki Nashimoto
Journal:  PLoS One       Date:  2015-03-02       Impact factor: 3.240

6.  The heptamer sgRNA targeting the human OCT4 mRNA can upregulate the OCT4 expression.

Authors:  Tadasuke Nozaki; Masayuki Takahashi; Tatsuya Ishikawa; Arisa Haino; Mineaki Seki; Hidetomo Kikuchi; Bo Yuan; Masayuki Nashimoto
Journal:  Biochem Biophys Rep       Date:  2021-02-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.